The Pharma Data
OCTOBER 18, 2020
Food and Drug Administration (FDA) for their at Home COVID-19 Nasal PCR Test. Since then, Eurofins has rolled out several highly sensitive and specific assays to thousands of clients nationwide, including hospitals, physicians’ offices, nursing homes, government entities, sports organizations and employers. Source link.
Pfizer
AUGUST 15, 2022
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. AUTHORIZED USE. anti-infectives). IMPORTANT SAFETY INFORMATION.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 2, 2022
Food and Drug Administration launched a new initiative, Supplement Your Knowledge , to help educate, inform, and broaden consumer, educator and healthcare professional understanding of dietary supplements. Today, the U.S. More than half of all Americans take dietary supplements daily or on occasion.
XTalks
NOVEMBER 7, 2023
Some may even extend their expertise to consumer goods sectors, including cosmetic brands. Calibrating drug strength, methodologies and dosages to facilitate large-scale manufacturing and distribution of pharmaceuticals and medicinal compounds. Innovating and evaluating medical equipment.
pharmaphorum
DECEMBER 15, 2022
We’re seeing everything from over-the-counter cold medication to cosmetic injection brands leverage different tiers of influencers. Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved.
Pfizer
DECEMBER 20, 2022
FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets).
Pfizer
DECEMBER 13, 2022
In June of 2022, Pfizer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID for patients who are at high risk of progression to severe disease from COVID-19. The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is in February 2023.
Expert insights. Personalized for you.
52 
Let's personalize your content